Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
RESEARCH TOOLSreports
Holding PRAX?
Track your performance easily
PRAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.78 - $86.93
Previous Close$72.75
Volume334.23K
Average Volume (3M)293.46K
Market Cap
$1.36B
Enterprise Value$1.00B
Total Cash (Recent Filing)$357.03M
Total Debt (Recent Filing)$1.66M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Mar 12, 2025EPS Estimate
-$2.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.29
Shares Outstanding18,637,777
10 Day Avg. Volume395,741
30 Day Avg. Volume293,465
Standard Deviation0.34
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.59
Price to Sales (P/S)845.85
Price to Cash Flow (P/CF)-12.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue624.16
Enterprise Value/Gross Profit408.88
Enterprise Value/Ebitda-6.63
Forecast
1Y Price Target
$144.50Price Target Upside96.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Praxis Precision Medicines News
PremiumCompany Announcements
Praxis Precision Medicines Reports Q3 2024 Results and Progress
PremiumCompany Announcements
Praxis Precision Advances CNS Disorder Therapies
PremiumCompany Announcements
Praxis Precision Updates Executive Severance PackagesBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPromising topline phase 2 EMBOLD trial results on persistent sodium channel inhibitor relutrigine in SCN2A and SCN8A provide strong early evidence that relutrigine will likely be a preferred treatment option for a subset of patients with developmental and epileptic encephalopathies.
Financial StabilityExpected cash runway into 2027 suggests strong financial stability for Praxis Precision Medicines, Inc.
Market OpportunityNegative competitor readouts have opened the ET market, presenting a significant commercial opportunity for PRAX.
Bears Say
EarningsPRAX reported an EPS of -$2.75, significantly lower (-38%) than the consensus EPS of -$1.99, primarily due to high operating expenses.
Financial PerformancePraxis Precision Medicines, Inc. reported a net loss of $52M for 3Q24, a notable increase from $33M in 2Q24, largely due to higher operational expenses.
Operational DelaysThe planned interim analysis for ESSENTIAL 3 study 1 has been delayed to the first quarter of 2025, potentially affecting investor confidence.
---
Ownership Overview
10.51% Insiders
13.65% Mutual Funds
48.89% Other Institutional Investors
13.90% Public Companies and Individual Investors
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $14.78 and its highest was $86.93 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Currently, no data Available
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Mar 12, 2025 which is in 111 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Nov 06, 2024. The company reported -$2.75 earnings per share for the quarter, missing the consensus estimate of -$1.989 by -$0.761.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -$2.79.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 18,637,777 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$2.75 in its last earnings report, missing expectations of -$1.989. Following the earnings report the stock price went down -1.182%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Among the largest hedge funds holding Praxis Precision Medicines’s share is RA Capital Management. It holds Praxis Precision Medicines’s shares valued at 71M.
---
Praxis Precision Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$144.50 (96.12% Upside)
$144.50 (96.12% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
370.87%
12-Months-Change
Fundamentals
Return on Equity
-64.34%
Trailing 12-Months
Asset Growth
290.03%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for patients and families affected by complex and debilitating brain disorders. The firm's pipeline covers PRAX-114, PRAX-944, PRAX-562, and PRAX-222 among others.
---
PRAX Earnings Call
Q3 2024
0:00 / 0:00
---
PRAX Stock 12 Month Forecast
Average Price Target
$144.50
▲(96.12% Upside)
Technical Analysis
Best Analysts Covering PRAX
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+107.28%
reiterated a buy rating 14 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +107.28% per trade.
---